24 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully
8-K
EX-10.2
vxayljcesn6
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
10-K
157ygr7
12 Mar 15
Annual report
12:00am
424B4
dz5vl3eijq vhl
5 Nov 14
Prospectus supplement with pricing info
12:00am